耐阿霉素肝癌细胞HepG2表达Fas的变化

CHANGES OF EXPRESSION Fas OF THE ADRIAMYCIN RESISTANCE HEPATIC CARCINOMA CELLS (HepG2 CELL LINES)

目的 探讨化疗中Fas与肿瘤细胞耐药性的关系。方法 采用细胞生物学方法建立耐阿霉素的肝癌细胞HepG2株 ,并应用免疫组织化学方法观察该耐药细胞Fas表达水平的变化。 结果 未经阿霉素诱导的不耐药的HepG2细胞仅弱表达Fas ,并主要在细胞膜 ;耐阿霉素的HepG2细胞表达Fas增强 ,并以胞浆为主。同时细胞的死亡率亦发生变化 ,耐药株在 0 .1μg/ml阿霉素中的死亡率与非耐药株在无ADM中死亡率比较差异无显著性意义 (P >0 .0 5 ) ,但与非耐药株在 0 .1μg/mlADM中的死亡率比较差异则有显著性意义 (P <0 .0 5 )。 结论 Fas表达水平的变化可能是体内癌细胞耐药的机理之一。

Objective To investigate the effect of the drug resistance characteristic of neoplasm cell on the expression of Fas during the chemical medi cure.[WT5”HZ]Methods [WT5”BZ]The adriamycin resistance hepatic carcinoma cells (HepG2 cell lines) were estabilished by cell biology. Changes of expression of the HepG2 cell lines was determined by immunohistochemistry. [WT5”HZ]Results [WT5”BZ]When the HepG2 cell lines were not induced by adriamycin, the expression of Fas of them was weak and Fas mainly existed in cell membrane. When induced by adriamycin, the expression was enhanced and Fas mainly existed in cytochylema. Simultaneously, the death rate of the cell lines changed. The death rate of the drug resistance cell lines in 0.1 μg/ml ADM was almost as same as that of non drug resistance cell lines without ADM ( P >0.05) and was significantly different from that of non drug resistance cell lines in 0.1 μg/ml ADM ( P <0.05). [WT5”HZ]Conclusion [WT5”BZ]Changes of the expression of Fas may be one of the drug resistance mechanisms of carcinoma cell.